Marie Hudson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marie Hudson has a total of 665 co-authors. Here are the top co-authors by number of shared publications:
Murray Baron
Department of Medicine, McGill University, Montreal, Quebec, and Division of Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada
27 shared publications- Murray Baron
McGill University
26 shared publications Russell Steele
21 shared publications- Brett D. Thombs
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada
16 shared publications Canadian Scleroderma Research Group
13 shared publications- Inés Colmegna
I. Colmegna, MD, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec
11 shared publications
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 38 (6) , 420-422
Updates on idiopathic inflammatory myopathies: partnering with patients, making progress
Was not provided for this article.
- 1 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 38 (6) , 420-422
Updates on idiopathic inflammatory myopathies: partnering with patients, making progress
Was not provided for this article.
- 15 June 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (9) , 1002-1012
Does the ACR/EULAR Total Improvement Score Reflect How Individuals With Autoimmune Inflammatory Myopathies Feel and Function?
Objective: Little is known as to whether the American College of Rheumatology/European Alliance of Associations for Rheumatology Total Improvement Score (TIS) reflects how patients with autoimmune inflammatory myopathies (AIM) feel and function. We assessed the associations between TIS and changes in the scores of a wide range of patient-reported outcomes (PROs). Methods: Adult patients with AIM and active disease at baseline who completed a 1-year follow-up visit were identified from a research cohort. PROs included a numerical rating scale for pain, the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue) scale, the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Fatigue 8a, the 9-item Patient Health Questionnaire (PHQ-9), and the 36-Item Short Form Health Survey (SF-36) physical and mental component summary scores (PCS and MCS, respectively). Multivariable linear regression models were generated to determine the absolute change in PRO scores for each 20-unit increase in absolute TIS. Results: We identified 65 patients with active disease for whom TIS could be calculated. At 1 year, 40% showed no improvement, 34% achieved minimal improvement, and 26% achieved moderate improvement. In adjusted models, increase in absolute TIS was associated with statistically significant improvements in pain, PROMIS-Fatigue, FACIT-Fatigue, and SF-36 PCS scores. For FACIT-Fatigue, a significant interaction was identified between age and TIS. In stratified analyses, only patients with shorter disease duration significantly improved in pain and FACIT-Fatigue scores. Conclusion: The findings of this cohort study support the use of the TIS in AIM research but also highlight potential limitations in its ability to capture outcomes across the broader AIM spectrum, particularly among older individuals and those with longer disease duration.
- 15 June 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (9) , 1002-1012
Does the ACR/EULAR Total Improvement Score Reflect How Individuals With Autoimmune Inflammatory Myopathies Feel and Function?
Objective: Little is known as to whether the American College of Rheumatology/European Alliance of Associations for Rheumatology Total Improvement Score (TIS) reflects how patients with autoimmune inflammatory myopathies (AIM) feel and function. We assessed the associations between TIS and changes in the scores of a wide range of patient-reported outcomes (PROs). Methods: Adult patients with AIM and active disease at baseline who completed a 1-year follow-up visit were identified from a research cohort. PROs included a numerical rating scale for pain, the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue) scale, the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Fatigue 8a, the 9-item Patient Health Questionnaire (PHQ-9), and the 36-Item Short Form Health Survey (SF-36) physical and mental component summary scores (PCS and MCS, respectively). Multivariable linear regression models were generated to determine the absolute change in PRO scores for each 20-unit increase in absolute TIS. Results: We identified 65 patients with active disease for whom TIS could be calculated. At 1 year, 40% showed no improvement, 34% achieved minimal improvement, and 26% achieved moderate improvement. In adjusted models, increase in absolute TIS was associated with statistically significant improvements in pain, PROMIS-Fatigue, FACIT-Fatigue, and SF-36 PCS scores. For FACIT-Fatigue, a significant interaction was identified between age and TIS. In stratified analyses, only patients with shorter disease duration significantly improved in pain and FACIT-Fatigue scores. Conclusion: The findings of this cohort study support the use of the TIS in AIM research but also highlight potential limitations in its ability to capture outcomes across the broader AIM spectrum, particularly among older individuals and those with longer disease duration.
- Open Access
- 15 June 2026
- Published by Wiley in Arthritis Care & Research
Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?
- 15 June 2026
- Published by Wiley in Arthritis Care & Research
Open AccessDistinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?
- Open Access
- 10 June 2026
- Published by Wiley in Arthritis Care & Research
Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey
Objective: Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc. Methods: An electronic REDCap survey was distributed to 756 general rheumatologists and 250 national and international SSc experts. Results: A total of 139 participants (14%) responded to the survey (94% were rheumatologists); 58% of respondents reported at least sometimes using immunosuppressive drugs to treat cutaneous symptoms in lcSSc, whereas 42% rarely or never did. Conversely, only 21% reported at least sometimes prescribing immunosuppression to prevent future complications in lcSSc, whereas 79% rarely or never did. Over 70% of respondents indicated that they would likely treat lcSSc in the presence of tendon friction rubs, new areas of skin thickening, increasing modified Rodnan skin scores (mRSSs), or mRSSs of 15 and above. Close to half would likely prescribe immunosuppression in the presence of mRSS of 10 to 14, anti‐topoisomerase I antibodies, or anti‐RNA polymerase III antibodies. Interestingly, a majority of respondents would likely treat lcSSc in the presence of subclinical organ involvement, including subclinical myocardial, muscle, joint, and lung disease. The top first‐line drugs of choice were mycophenolate mofetil (47%), methotrexate (28%), and hydroxychloroquine (20%). Conclusion: This international survey highlights significant heterogeneity among rheumatologists in the use of immunosuppressive drugs in lcSSc. High‐quality research is needed to guide and harmonize the approach to management in lcSSc.
- 10 June 2026
- Published by Wiley in Arthritis Care & Research
Open AccessImmunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey
Objective: Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc. Methods: An electronic REDCap survey was distributed to 756 general rheumatologists and 250 national and international SSc experts. Results: A total of 139 participants (14%) responded to the survey (94% were rheumatologists); 58% of respondents reported at least sometimes using immunosuppressive drugs to treat cutaneous symptoms in lcSSc, whereas 42% rarely or never did. Conversely, only 21% reported at least sometimes prescribing immunosuppression to prevent future complications in lcSSc, whereas 79% rarely or never did. Over 70% of respondents indicated that they would likely treat lcSSc in the presence of tendon friction rubs, new areas of skin thickening, increasing modified Rodnan skin scores (mRSSs), or mRSSs of 15 and above. Close to half would likely prescribe immunosuppression in the presence of mRSS of 10 to 14, anti‐topoisomerase I antibodies, or anti‐RNA polymerase III antibodies. Interestingly, a majority of respondents would likely treat lcSSc in the presence of subclinical organ involvement, including subclinical myocardial, muscle, joint, and lung disease. The top first‐line drugs of choice were mycophenolate mofetil (47%), methotrexate (28%), and hydroxychloroquine (20%). Conclusion: This international survey highlights significant heterogeneity among rheumatologists in the use of immunosuppressive drugs in lcSSc. High‐quality research is needed to guide and harmonize the approach to management in lcSSc.
- Open Access
- 27 May 2026
- Published by Elsevier in SSRN Electronic Journal
Anti-synthetase Syndrome–Associated Interstitial Lung Disease: Clinical Features and Outcomes Compared with Other ILDs
Objectives: To identify clinical features distinguishing anti-synthetase syndrome (ASyS)-related ILD (ASyS-ILD) from non-ASyS ILD and to compare outcomes across ILD subgroups.Methods: We utilized an international, real-world physician-reported database to compare ASyS-ILD and ILD related to other causes. Comparative analysis was performed against the overall control group, and the five main control ILD disease subgroups. Logistic regression assessed associations with supplemental oxygen use and ILD-hospitalization, and Cox proportional hazards models evaluated associations with all-cause mortality. Results: Among 1,557 ASyS-ILD and 828 controls, ASyS-ILD patients were younger, had more acute onset, and had worse restrictive physiology. Nonspecific interstitial pneumonia (NSIP) was the most common radiological pattern across all groups. In ASyS-ILD, NSIP (55%) was followed by organizing pneumonia (OP, 19%), similar to ILD in dermatomyositis (DM) with and without MDA5 antibodies (NSIP 53% and 64%, OP 32% and 11%, respectively). NSIP remained common in rheumatoid arthritis (RA) and systemic sclerosis (SSc) ILD (39% and 59%) but was followed by usual interstitial pneumonia (36% and 14%). Compared with controls, ASyS-ILD had higher odds of hospitalization (OR 1.81, 95%CI 1.38-2.37). Mortality in ASyS-ILD was primarily pulmonary then cardiovascular, Five-year survival in ASyS-ILD was 94.7% which was comparable or higher than most control subgroups, except anti-MDA5-associated ILD (90.3%). ASyS-ILD had higher all-cause mortality (HR 1.66, 95%CI 1.03–2.66) than controls. Conclusions: ASyS-ILD is characterized by a younger, more acute, and symptomatic onset compared with other ILDs, and is associated with higher hospitalization rates and worse mortality, underscoring its overall more severe clinical course.
- 27 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAnti-synthetase Syndrome–Associated Interstitial Lung Disease: Clinical Features and Outcomes Compared with Other ILDs
Objectives: To identify clinical features distinguishing anti-synthetase syndrome (ASyS)-related ILD (ASyS-ILD) from non-ASyS ILD and to compare outcomes across ILD subgroups.Methods: We utilized an international, real-world physician-reported database to compare ASyS-ILD and ILD related to other causes. Comparative analysis was performed against the overall control group, and the five main control ILD disease subgroups. Logistic regression assessed associations with supplemental oxygen use and ILD-hospitalization, and Cox proportional hazards models evaluated associations with all-cause mortality. Results: Among 1,557 ASyS-ILD and 828 controls, ASyS-ILD patients were younger, had more acute onset, and had worse restrictive physiology. Nonspecific interstitial pneumonia (NSIP) was the most common radiological pattern across all groups. In ASyS-ILD, NSIP (55%) was followed by organizing pneumonia (OP, 19%), similar to ILD in dermatomyositis (DM) with and without MDA5 antibodies (NSIP 53% and 64%, OP 32% and 11%, respectively). NSIP remained common in rheumatoid arthritis (RA) and systemic sclerosis (SSc) ILD (39% and 59%) but was followed by usual interstitial pneumonia (36% and 14%). Compared with controls, ASyS-ILD had higher odds of hospitalization (OR 1.81, 95%CI 1.38-2.37). Mortality in ASyS-ILD was primarily pulmonary then cardiovascular, Five-year survival in ASyS-ILD was 94.7% which was comparable or higher than most control subgroups, except anti-MDA5-associated ILD (90.3%). ASyS-ILD had higher all-cause mortality (HR 1.66, 95%CI 1.03–2.66) than controls. Conclusions: ASyS-ILD is characterized by a younger, more acute, and symptomatic onset compared with other ILDs, and is associated with higher hospitalization rates and worse mortality, underscoring its overall more severe clinical course.
- Open Access
- 6 April 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (4) , e90027
Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders
Objective: Our objective was to develop a brief Support Group Leader Self‐efficacy Scale (Brief‐SGLSS) that maintains the core content and measurement properties of the full 32‐item SGLSS among systemic sclerosis (SSc) support group leaders. Methods: Development and validation involved four steps conducted by researchers and a Support Group Advisory Team of people with SSc: (1) item content assessment and prioritization, including a Delphi process; (2) item analysis and preliminary selection, including analysis of SGLSS measurement properties using Scleroderma Patient‐centered Intervention Network–Scleroderma‐Support group Leader Education (SPIN‐SSLED) trial data and a data‐driven item resampling process; (3) advisory team input to select final Brief‐SGLSS items; and (4) comparison of convergent validity and trial change data of the Brief‐SGLSS and full SGLSS. Results: Items were categorized into six content themes. Two Delphi rounds resulted in one item excluded from consideration. A 6‐item Brief‐SGLSS was selected at the consensus advisory panel meeting based on the resampling process and content and statistical considerations. The Pearson correlation of the Brief‐SGLSS and full SGLSS was 0.96. The standardized mean difference between intervention (n = 74) and waitlist (n = 72) groups in the SPIN‐SSLED trial immediately post intervention was 0.93 (95% confidence interval [CI] 0.59–1.27) for the full 32‐item SGLSS and 0.93 (95% CI 0.58–1.27) for the Brief‐SGLSS. Convergent validity of the Brief‐SGLSS and full SGLSS with other measures was similar. Conclusion: The 6‐item SGLSS is shorter and more feasibly implemented than the full SGLSS and maintains similar measurement properties.
- 6 April 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (4) , e90027
Open AccessDevelopment and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders
Objective: Our objective was to develop a brief Support Group Leader Self‐efficacy Scale (Brief‐SGLSS) that maintains the core content and measurement properties of the full 32‐item SGLSS among systemic sclerosis (SSc) support group leaders. Methods: Development and validation involved four steps conducted by researchers and a Support Group Advisory Team of people with SSc: (1) item content assessment and prioritization, including a Delphi process; (2) item analysis and preliminary selection, including analysis of SGLSS measurement properties using Scleroderma Patient‐centered Intervention Network–Scleroderma‐Support group Leader Education (SPIN‐SSLED) trial data and a data‐driven item resampling process; (3) advisory team input to select final Brief‐SGLSS items; and (4) comparison of convergent validity and trial change data of the Brief‐SGLSS and full SGLSS. Results: Items were categorized into six content themes. Two Delphi rounds resulted in one item excluded from consideration. A 6‐item Brief‐SGLSS was selected at the consensus advisory panel meeting based on the resampling process and content and statistical considerations. The Pearson correlation of the Brief‐SGLSS and full SGLSS was 0.96. The standardized mean difference between intervention (n = 74) and waitlist (n = 72) groups in the SPIN‐SSLED trial immediately post intervention was 0.93 (95% confidence interval [CI] 0.59–1.27) for the full 32‐item SGLSS and 0.93 (95% CI 0.58–1.27) for the Brief‐SGLSS. Convergent validity of the Brief‐SGLSS and full SGLSS with other measures was similar. Conclusion: The 6‐item SGLSS is shorter and more feasibly implemented than the full SGLSS and maintains similar measurement properties.
- 7 March 2026
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 40 (2) , 102126
Scleromyositis – The new frontier
- 7 March 2026
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 40 (2) , 102126
Scleromyositis – The new frontier
- 17 February 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (5) , 1022-1024
Getting It Right for Our Patients
- 17 February 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (5) , 1022-1024
Getting It Right for Our Patients